Investigational drug · Phase 2
LTT462
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Melanoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Mar 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
5
Any phase or sponsor naming "LTT462"
First trial start
2020
Oct 30, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "LTT462", any sponsor or status.
Conditions studied
As listed on its trial records.
- Melanoma
Largest trials
Live from ClinicalTrials.gov: studies naming "LTT462" as an intervention, largest first.
Novartis PharmaceuticalsNovartis (NVS)
NCT02974725 · 241 participants · Start Feb 24, 2017 · Primary completion Apr 24, 2024
Drug: LXH254; LTT462 and 2 more · For: Non-Small Cell Lung Cancer; Melanoma
Sites: San Diego, California; San Francisco, California; Boston, Massachusetts · 32 sites in all
- Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic MelanomaPivotal-lookingActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT04417621 · 134 participants · Start Oct 30, 2020 · Primary completion Feb 2, 2027
Drug: LXH254; LTT462 and 2 more · For: Melanoma
Sites: Los Angeles, California; San Francisco, California; Fort Myers, Florida · 36 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT04294160 · 122 participants · Start Jul 22, 2020 · Primary completion Sep 25, 2024
Drug: Dabrafenib; LTT462 and 5 more · For: BRAF V600 Colorectal Cancer
Sites: Los Angeles, California; Boston, Massachusetts; Nashville, Tennessee · 18 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT02711345 · 65 participants · Start Apr 15, 2016 · Primary completion Nov 21, 2018
Drug: LTT462 · For: Ovarian Neoplasms; Non-Small-Cell Lung Carcinoma; Melanoma and 1 more
Sites: New York, New York; Houston, Texas; Essen, Germany · 7 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT04097821 · 45 participants · Start Sep 26, 2019 · Primary completion May 3, 2023
Drug: Ruxolitinib; Siremadlin and 4 more · For: Myelofibrosis
Sites: Adelaide, Australia; Melbourne, Australia; Toronto, Canada · 22 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Dermatologic Toxicities Associated With Novel Pan-RAS/RAF Inhibitors.
He LJ, Hegazy S, Aung PP, et al. · J Cutan Pathol 2026
- A phase Ib study of the combination of naporafenib with rineterkib or trametinib in patients with advanced and metastatic KRAS- or BRAF-mutant non-small cell lung cancer.
Planchard D, Wolf J, Solomon B, et al. · Lung Cancer 2024
Also in development for Melanoma
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- FianlimabREGN3767Phase 311 trials
Regeneron · Melanoma, Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- IfebemtinibIN10018, BI853520Phase 311 trials
InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer
- Intismeran autogeneV940, mRNA-4157Phase 310 trials
Merck & Co. · Non-small Cell Lung Cancer, Melanoma, Bladder Cancer
- FavezelimabMK-4280, MK-4820APhase 39 trials
Merck & Co. · Melanoma, Carcinoma, Renal Cell, Solid Tumors
- IBI363Phase 37 trials
Innovent Biologics (Suzhou) Co. Ltd. · Melanoma, Colorectal Cancer, Resectable Stage II-III Non-small Cell Lung Cancer
- OH2Phase 36 trials
Binhui Biopharmaceutical Co., Ltd. · Melanoma, Solid Tumor, Gastrointestinal Cancer
- PucotenlimabHX008Phase 36 trials
Lepu Biopharma Co., Ltd. · Head and Neck Squamous Cell Carcinoma, Melanoma, Hepatocellular Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Novartis.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.